Long-Term Effects of Iron Chelating Agents on Ocular Function in Patients with Thalassemia Major
Raffaele Nuzzi,1 Giada Geronazzo,1,2 Federico Tridico,1 Alessia Nuzzi,3 Paolo Caselgrandi,1 Antonio Giulio Piga4 1Eye Clinic Section, Department of Surgical Sciences, University of Turin, Turin, Italy; 2Regional Reference Centre for Diagnosis and Cure of Hemoglobinopathies, S. Luigi Gonzaga Universi...
Guardado en:
Autores principales: | Nuzzi R, Geronazzo G, Tridico F, Nuzzi A, Caselgrandi P, Piga AG |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/55e38c48e15346089a76b4635cefb219 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Iron chelation therapy with deferiprone improves oxidative status and red blood cell quality and reduces redox-active iron in β-thalassemia/hemoglobin E patients
por: Noppawan Phumala Morales, et al.
Publicado: (2022) -
An overview of complications associated with deferoxamine therapy in thalassemia
por: Bijan Keikhaei, et al.
Publicado: (2021) -
Biofortification of cowpea beans with iron: iron´s influence on mineral content and yield
por: Márquez-Quiroz,C, et al.
Publicado: (2015) -
Prognostic Factors and Clinical Considerations for Iron Chelation Therapy in Myelodysplastic Syndrome Patients
por: Parisi S, et al.
Publicado: (2021) -
Chelators for Treatment of Iron and Copper Overload: Shift from Low-Molecular-Weight Compounds to Polymers
por: Martin Hruby, et al.
Publicado: (2021)